tredaptive (nicotinic acid/ laropiprant) + placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Polycystic Ovary Syndrome
Conditions
Polycystic Ovary Syndrome
Trial Timeline
Jun 1, 2010 → May 1, 2012
NCT ID
NCT01118598About tredaptive (nicotinic acid/ laropiprant) + placebo
tredaptive (nicotinic acid/ laropiprant) + placebo is a approved stage product being developed by Merck for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01118598. Target conditions include Polycystic Ovary Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01118598 | Approved | Completed |
Competing Products
20 competing products in Polycystic Ovary Syndrome